Delayed Administration of Ixazomib Modifies the Immune Response and Prevents Chronic Graft-versus-Host Disease

Investigators aimed to modify the immune response in the long term after allogeneic bone marrow transplantation by using the proteasome inhibitor ixazomib at the late stages of the post-transplant period.